Healthcare / Healthcare PlansXETRA
$327.20
+4.20 (+1.30%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $20.7B · quality 71.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$297.1B
P/E
28.7x
↑EV/EBITDA
15.3x
↑ROE
12.8%
↑Gross Margin
18.5%
↓Debt/Equity
0.83
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.4%
FCF CAGR
-11.8%
FCF margin
3.6%
FCF / Net income
1.33x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $447.57B · net income $12.06B · FCF $16.07B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $447.57B | $447.57B | $400.28B | $371.62B | $324.16B |
| Net Income | $12.06B | $12.06B | $14.40B | $22.38B | $20.12B |
| EBITDA | $23.06B | $23.06B | $28.08B | $36.33B | $31.84B |
| EPS | 13.23 | 13.23 | 15.51 | 23.86 | 21.18 |
| Gross Margin | 18.5% | 18.5% | 22.3% | 24.5% | 24.6% |
| Operating Margin | 4.2% | 4.2% | 8.1% | 8.7% | 8.8% |
| Net Margin | 2.7% | 2.7% | 3.6% | 6.0% | 6.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.83 | 0.83 | 0.83 | 0.70 | 0.74 |
| Current Ratio | 0.80 | 0.80 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $16.07B | $16.07B | $20.70B | $25.68B | $23.40B |
| Returns | |||||
| ROE | 12.8% | 12.8% | 15.5% | 25.2% | 25.9% |
| Valuation | |||||
| P/E | 28.70 | 28.70 | 32.21 | 20.52 | 21.74 |
| EV/EBITDA | 15.27 | 15.27 | 18.37 | 13.66 | 14.82 |
| P/B | 3.17 | 3.17 | 5.01 | 5.17 | 5.62 |
| Growth & Yield | |||||
| Revenue Growth | 11.8% | 11.8% | 7.7% | 14.6% | — |
| EPS Growth | -14.7% | -14.7% | -35.0% | 12.7% | — |
| Dividend Yield | 2.4% | 2.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
30.0%
EPS terminal req.
$29.03
Spread vs growth
-44.7%
5Y implied EPS CAGR
21.6%
EPS terminal req.
$35.13
Spread vs growth
-36.3%
10Y implied EPS CAGR
15.6%
EPS terminal req.
$56.58
Spread vs growth
-30.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+25.5%
Start / end P/E
17.1x → 24.7x
EPS bridge
15.51 → 13.23
Residual
-6.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.